<p>CervoMed Inc.（納斯達克代碼：CRVO - 免費報告）- Roth Capital 的研究分析師在 8 月 11 日星期一向投資者發佈的報告中下調了對 CervoMed 2025 年第三季度每股收益的預期。Roth Capital 分析師 B. Pachaiyappan 現在預測該公司本季度每股收益為（$0.76），低於之前預測的（$0.50）。Roth Capital 目前對該股票的評級為 “買入”，目標價為 16.00 美元。市場普遍預期 CervoMed 當前全年的每股收益為（$1.88）。Roth Capital 還對 CervoMed 2025 年第四季度的每股收益預期為（$0.49），2025 財年的每股收益預期為（$2.51），2026 年第一季度的每股收益預期為（$0.61），2026 年第二季度的每股收益預期為（$0.63），2026 年第三季度的每股收益預期為（$0.71），2026 年第四季度的每股收益預期為（$0.75），以及 2026 財年的每股收益預期為（$2.71）。</p>
<p>CervoMed（納斯達克代碼：CRVO - 獲取免費報告）最近於 8 月 8 日星期五發布了季度財報。該公司報告本季度每股收益為（$0.70），低於分析師普遍預期的（$0.57），差額為（$0.13）。CervoMed 的淨利潤率為負的 290.72%，股本回報率為負的 59.15%。該公司本季度的收入為 176 萬美元，而分析師預期為 145 萬美元。</p>
<p>其他一些研究公司也最近對 CRVO 發表了評論。Canaccord Genuity Group 將 CervoMed 的目標股價從 21.00 美元上調至 27.00 美元，並在 7 月 29 日的研究報告中給予該股票 “買入” 評級。Chardan Capital 在週一重申了 “買入” 評級，並將 CervoMed 的目標價設定為 15.00 美元。最後，D. Boral Capital 在週一將 CervoMed 的目標股價從 10.00 美元上調至 15.00 美元，並給予該公司 “買入” 評級。一位股票研究分析師對該股票給予了賣出評級，一位給予了持有評級，六位給予了買入評級，還有一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識目標價為 21.43 美元。</p>
<p><strong>查看我們對 CRVO 的最新分析</strong></p>
<h2>CervoMed 股票表現</h2>
<p>CRVO 週四開盤價為 9.64 美元。CervoMed 的 52 周最低價為 1.80 美元，最高價為 20.63 美元。該公司的 50 日移動平均線為 7.64 美元，200 日移動平均線為 7.05 美元。該股票的市值為 8920 萬美元，市盈率為-3.69，貝塔值為-0.79。</p>
<h2>對 CervoMed 的對沖基金看法</h2>
<p>幾家大型投資者最近對 CRVO 的持倉進行了調整。Rhumbline Advisers 在第一季度將其在 CervoMed 的股份增加了 35.5%。Rhumbline Advisers 目前擁有 5830 股該公司的股票，價值 53,000 美元，此前在此期間又購買了 1526 股。HighTower Advisors LLC 在第一季度購買了 CervoMed 的新股份，價值約為 104,000 美元。Marshall Wace LLP 在第二季度購買了 CervoMed 的新股份，價值約為 76,000 美元。紐約梅隆銀行在第一季度購買了 CervoMed 的新股份，價值為 110,000 美元。最後，Mariner LLC 在第四季度購買了 CervoMed 的新股份，價值為 30,000 美元。目前，25.15% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 CervoMed</h2>
<p>（獲取免費報告）</p>
<p>CervoMed Inc. 是一家生物技術公司，專注於開發和商業化針對與年齡相關的神經系統疾病的治療。其主要藥物候選者是 neflamapimod，這是一種口服小分子藥物，能夠穿透大腦，用於治療路易體痴呆（DLB）、阿爾茨海默病、額顳葉痴呆和缺血性中風恢復。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 CervoMed</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>數據中心為這三隻核能股票創造了牛市前景</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>特斯拉的旗形圖形剛剛破裂：這對股票意味着什麼</li>
<li>如何使用 MarketBeat 股息計算器</li>
<li>三家公司將從特朗普的半導體關税中獲利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 CervoMed 嗎？</h2>
<p>在考慮 CervoMed 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CervoMed 並不在名單上。</p>
<p>雖然 CervoMed 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CRVO

<p>Roth Capital 已將 CervoMed Inc. (NASDAQ:CRVO) 2025 年第三季度每股收益（EPS）預估從（$0.50）下調至（$0.76）。該公司維持 “買入” 評級，目標價為 $16.00。CervoMed 最近的財報顯示每股虧損（$0.70），未能達到預期。分析師對該股票的評級不一，平均評級為 “適度買入”，共識目標價為 $21.43。CervoMed 專注於治療與年齡相關的神經系統疾病，其主要候選藥物為 neflamapimod</p>

<p>CervoMed Inc. (NASDAQ:CRVO - Free Report) - Research analysts at Roth Capital cut their Q3 2025 EPS estimates for CervoMed in a note issued to investors on Monday, August 11th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their previous forecast of ($0.50). Roth Capital currently has a &#34;Buy&#34; rating and a $16.00 price target on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed's Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($2.51) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.71) EPS.</p>
<div class="lb-trans"><p>CervoMed Inc.（納斯達克代碼：CRVO - 免費報告）- Roth Capital 的研究分析師在 8 月 11 日星期一向投資者發佈的報告中下調了對 CervoMed 2025 年第三季度每股收益的預期。Roth Capital 分析師 B. Pachaiyappan 現在預測該公司本季度每股收益為（$0.76），低於之前預測的（$0.50）。Roth Capital 目前對該股票的評級為 “買入”，目標價為 16.00 美元。市場普遍預期 CervoMed 當前全年的每股收益為（$1.88）。Roth Capital 還對 CervoMed 2025 年第四季度的每股收益預期為（$0.49），2025 財年的每股收益預期為（$2.51），2026 年第一季度的每股收益預期為（$0.61），2026 年第二季度的每股收益預期為（$0.63），2026 年第三季度的每股收益預期為（$0.71），2026 年第四季度的每股收益預期為（$0.75），以及 2026 財年的每股收益預期為（$2.71）。</p>
</div><p>CervoMed (NASDAQ:CRVO - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. The firm had revenue of $1.76 million during the quarter, compared to analysts' expectations of $1.45 million.</p>
<div class="lb-trans"><p>CervoMed（納斯達克代碼：CRVO - 獲取免費報告）最近於 8 月 8 日星期五發布了季度財報。該公司報告本季度每股收益為（$0.70），低於分析師普遍預期的（$0.57），差額為（$0.13）。CervoMed 的淨利潤率為負的 290.72%，股本回報率為負的 59.15%。該公司本季度的收入為 176 萬美元，而分析師預期為 145 萬美元。</p>
</div><p>A number of other research firms have also recently commented on CRVO. Canaccord Genuity Group boosted their target price on shares of CervoMed from $21.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, July 29th. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $15.00 price objective on shares of CervoMed in a research note on Monday. Finally, D. Boral Capital boosted their target price on shares of CervoMed from $10.00 to $15.00 and gave the company a &#34;buy&#34; rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $21.43.</p>
<div class="lb-trans"><p>其他一些研究公司也最近對 CRVO 發表了評論。Canaccord Genuity Group 將 CervoMed 的目標股價從 21.00 美元上調至 27.00 美元，並在 7 月 29 日的研究報告中給予該股票 “買入” 評級。Chardan Capital 在週一重申了 “買入” 評級，並將 CervoMed 的目標價設定為 15.00 美元。最後，D. Boral Capital 在週一將 CervoMed 的目標股價從 10.00 美元上調至 15.00 美元，並給予該公司 “買入” 評級。一位股票研究分析師對該股票給予了賣出評級，一位給予了持有評級，六位給予了買入評級，還有一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識目標價為 21.43 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on CRVO</strong></p>
<div class="lb-trans"><p><strong>查看我們對 CRVO 的最新分析</strong></p>
</div><h2>CervoMed Stock Performance</h2>
<div class="lb-trans"><h2>CervoMed 股票表現</h2>
</div><p>CRVO opened at $9.64 on Thursday. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $20.63. The company has a fifty day moving average of $7.64 and a two-hundred day moving average of $7.05. The stock has a market capitalization of $89.20 million, a price-to-earnings ratio of -3.69 and a beta of -0.79.</p>
<div class="lb-trans"><p>CRVO 週四開盤價為 9.64 美元。CervoMed 的 52 周最低價為 1.80 美元，最高價為 20.63 美元。該公司的 50 日移動平均線為 7.64 美元，200 日移動平均線為 7.05 美元。該股票的市值為 8920 萬美元，市盈率為-3.69，貝塔值為-0.79。</p>
</div><h2>Hedge Funds Weigh In On CervoMed</h2>
<div class="lb-trans"><h2>對 CervoMed 的對沖基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in CRVO. Rhumbline Advisers increased its stake in CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after buying an additional 1,526 shares during the period. HighTower Advisors LLC purchased a new stake in shares of CervoMed in the 1st quarter valued at approximately $104,000. Marshall Wace LLP purchased a new stake in shares of CervoMed in the 2nd quarter valued at approximately $76,000. Bank of New York Mellon Corp purchased a new position in shares of CervoMed in the 1st quarter valued at $110,000. Finally, Mariner LLC purchased a new position in shares of CervoMed in the 4th quarter valued at $30,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家大型投資者最近對 CRVO 的持倉進行了調整。Rhumbline Advisers 在第一季度將其在 CervoMed 的股份增加了 35.5%。Rhumbline Advisers 目前擁有 5830 股該公司的股票，價值 53,000 美元，此前在此期間又購買了 1526 股。HighTower Advisors LLC 在第一季度購買了 CervoMed 的新股份，價值約為 104,000 美元。Marshall Wace LLP 在第二季度購買了 CervoMed 的新股份，價值約為 76,000 美元。紐約梅隆銀行在第一季度購買了 CervoMed 的新股份，價值為 110,000 美元。最後，Mariner LLC 在第四季度購買了 CervoMed 的新股份，價值為 30,000 美元。目前，25.15% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About CervoMed</h2>
<div class="lb-trans"><h2>關於 CervoMed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.</p>
<div class="lb-trans"><p>CervoMed Inc. 是一家生物技術公司，專注於開發和商業化針對與年齡相關的神經系統疾病的治療。其主要藥物候選者是 neflamapimod，這是一種口服小分子藥物，能夠穿透大腦，用於治療路易體痴呆（DLB）、阿爾茨海默病、額顳葉痴呆和缺血性中風恢復。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than CervoMed</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Data Centers Create a Bull Case for These Nuclear 3 Stocks</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>3 Companies That Will Profit From Trump's Semiconductor Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 CervoMed</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>數據中心為這三隻核能股票創造了牛市前景</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>特斯拉的旗形圖形剛剛破裂：這對股票意味着什麼</li>
<li>如何使用 MarketBeat 股息計算器</li>
<li>三家公司將從特朗普的半導體關税中獲利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CervoMed Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 CervoMed 嗎？</h2>
</div><p>Before you consider CervoMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CervoMed 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CervoMed 並不在名單上。</p>
</div><p>While CervoMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CervoMed 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

羅斯資本對 CervoMed 第三季度收益的預測持悲觀態度